Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haskell, H.
Right arrow Articles by Gladson, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haskell, H.
Right arrow Articles by Gladson, C. L.
Clinical Cancer Research Vol. 9, 2157-2165, June 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Focal Adhesion Kinase Is Expressed in the Angiogenic Blood Vessels of Malignant Astrocytic Tumors in Vivo and Promotes Capillary Tube Formation of Brain Microvascular Endothelial Cells1

Henry Haskell2, Meera Natarajan2, Timothy P. Hecker, Qiang Ding, Jerry Stewart, Jr., J. Robert Grammer and Candece L. Gladson3

Department of Pathology, Division of Neuropathology [H. H., M. N., T. P. H., Q. D., J. S., J. R. G., C. L. G.], and The Medical Scientist Training Program [T. P. H.], University of Alabama at Birmingham, Birmingham, Alabama 35294

Purpose: Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that has been shown to promote proliferation, migration, and invasion of several cell types in vitro, and we have shown recently that FAK promotes proliferation of malignant astrocytoma cells in vivo. To determine the role of FAK in angiogenesis in malignant astrocytic tumors, we investigated the expression and function of FAK in brain endothelial cells.

Experimental Design: We characterized the expression of FAK and activated FAK in endothelial cells by immunohistochemistry. We also determined the function of FAK in brain microvascular endothelial cells by transfecting these cells with a dominant interfering form of FAK [FAK-related nonkinase (FRNK)] or a mutant FRNK (Leu-1034 to Ser) and assessed the effect on capillary tube formation and cell migration.

Results: We found that FAK was expressed in the endothelial cells of grade III (4 of 9 samples) and IV (9 of 10 samples) astrocytoma biopsies but not in the endothelial cells of normal brain (0 of 9 samples) and not in grade I (0 of 5 samples) or II (0 of 4 samples) astrocytoma biopsies. Furthermore, we found that both FAK and activated FAK were expressed in the endothelial cells in malignant astrocytoma tumors propagated intracerebrally in the severe combined immunodeficient mouse brain. As expected, immunofluorescence analysis showed FRNK protein to localize to focal adhesions, whereas mutant FRNK protein did not. FRNK-transfected endothelial cells showed a 55% reduction in branched tube formation and a 40% reduction in tube length when propagated in three-dimensional collagen gels, compared with cells transfected with the mutant FRNK construct. Furthermore, FRNK-transfected cells showed a 35–50% reduction in haptotactic migration toward fibronectin and collagen, compared with mutant FRNK-transfected cells.

Conclusions: These data suggest that FAK promotes angiogenesis and that this occurs, at least in part, through the promotion of endothelial cell migration.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Q. Ding, C. L. Gladson, H. Wu, H. Hayasaka, and M. A. Olman
Focal Adhesion Kinase (FAK)-related Non-kinase Inhibits Myofibroblast Differentiation through Differential MAPK Activation in a FAK-dependent Manner
J. Biol. Chem., October 3, 2008; 283(40): 26839 - 26849.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. G. Roberts, E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E. Emerson, J. Lin, J. Kath, et al.
Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271
Cancer Res., March 15, 2008; 68(6): 1935 - 1944.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Halder, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, T. Honda, A. A. Kamat, L. Y. Han, T. J. Kim, C. Lu, et al.
Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma
Cancer Res., November 15, 2007; 67(22): 10976 - 10983.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T.-J. Liu, T. LaFortune, T. Honda, O. Ohmori, S. Hatakeyama, T. Meyer, D. Jackson, J. de Groot, and W.K. A. Yung
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo
Mol. Cancer Ther., April 1, 2007; 6(4): 1357 - 1367.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. R. Hess, L.-M. Postovit, N. V. Margaryan, E. A. Seftor, G. B. Schneider, R. E.B. Seftor, B. J. Nickoloff, and M. J.C. Hendrix
Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
Cancer Res., November 1, 2005; 65(21): 9851 - 9860.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Y. Fears, J. R. Grammer, J. E. Stewart Jr., D. S. Annis, D. F. Mosher, P. Bornstein, and C. L. Gladson
Low-Density Lipoprotein Receptor-Related Protein Contributes to the Antiangiogenic Activity of Thrombospondin-2 in a Murine Glioma Model
Cancer Res., October 15, 2005; 65(20): 9338 - 9346.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
T.-L. Shen, A. Y.-J. Park, A. Alcaraz, X. Peng, I. Jang, P. Koni, R. A. Flavell, H. Gu, and J.-L. Guan
Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis
J. Cell Biol., June 20, 2005; 169(6): 941 - 952.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. M. Belkin, G. Tsurupa, E. Zemskov, Y. Veklich, J. W. Weisel, and L. Medved
Transglutaminase-mediated oligomerization of the fibrin(ogen) {alpha}C domains promotes integrin-dependent cell adhesion and signaling
Blood, May 1, 2005; 105(9): 3561 - 3568.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
T. A. Rege, C. Y. Fears, and C. L. Gladson
Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy
Neuro-oncol, April 1, 2005; 7(2): 106 - 121.
[Abstract] [PDF]


Home page
Cancer Res.Home page
S.-H. Lee, M. J. Son, S.-H. Oh, S.-B. Rho, K. Park, Y.-J. Kim, M.-S. Park, and J.-H. Lee
Thymosin {beta}10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function
Cancer Res., January 1, 2005; 65(1): 137 - 148.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. T. Rizzo
Focal adhesion kinase and angiogenesis. Where do we go from here?
Cardiovasc Res, December 1, 2004; 64(3): 377 - 378.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Le Boeuf, F. Houle, and J. Huot
Regulation of Vascular Endothelial Growth Factor Receptor 2-mediated Phosphorylation of Focal Adhesion Kinase by Heat Shock Protein 90 and Src Kinase Activities
J. Biol. Chem., September 10, 2004; 279(37): 39175 - 39185.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.